Universit tsklinikum Carl Gustav Carus Dresden(7.4 mi away)Contact
+13 other location
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder and
therapeutic options are limited. The rho kinase (ROCK) inhibitor Fasudil was shown to be
neuroprotective, induced axonal regeneration and improved survival and behavioral outcome in
models of ALS and other neurodegenerative diseases. The aim of this phase IIa, multi-center
and double-blind study is to analyze the safety, tolerability and efficacy of fasudil in two
different doses compared to placebo in approximately 16 trial sites in Germany, France and
Switzerland. Intravenous application of fasudil will be performed in 80 patients and placebo
in 40 patients two times daily for 20 treatment days. The hypothesis is that fasudil is safe
and well-tolerated and its application will significantly improve the clinical outcome in
patients with ALS.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.